Recently, cutaneous adnexal carcinomas including DPAC have been found to express Nectin-4 [7]; the anti-nectin-4 antibody-drug conjugate enfortunab-vedotin, recently FDA- and EMA-approved for locally advanced or metastasized bladder carcinoma [8], may have enough potential that is should be considered for advanced DPAC. Here, NECTIN4 is linked to urinary bladder carcinoma.